The CREDENCE study confirmed that the SGLT-2 inhibitor, canagliflozin, carries the advantages of effective hypoglycemia and improved renal outcomes in DM patients with chronic kidney disease (CKD) [11, 12], which has led it to be recommended by several authoritative guidelines as the optimal hypoglycemic scheme for diabetes patients with CKD, highlighting the position of SGLT-2 inhibitors in secondary prevention of diabetic nephropathy. This evidence concerns the gene SLC5A2 and diabetic kidney disease.